Osteoporosis secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 10: Line 10:
==Secondary prevention==
==Secondary prevention==
===Medication===
===Medication===
Just as for treatment, [[bisphosphonate]] can be used in cases of very high risk. Other medicines prescribed for prevention of osteoporosis include [[raloxifene]] (Evista), a [[selective estrogen receptor modulator]] (SERM).  
Just as for treatment, [[bisphosphonate]]<ref name="pmid22805729">{{cite journal |author=Zhang J, Wang R, Zhao YL, ''et al.'' |title=Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis |journal=Asian Pac J Trop Med |volume=5 |issue=9 |pages=743–8 |year=2012 |month=September |pmid=22805729 |doi=10.1016/S1995-7645(12)60118-7 |url=}}</ref> can be used in cases of very high risk. Other medicines prescribed for prevention of osteoporosis include [[raloxifene]] (Evista), a [[selective estrogen receptor modulator]] (SERM).  


Estrogen replacement remains a good treatment for prevention of osteoporosis but, at this time, is not recommended unless there are other indications for its use as well. There is uncertainty and controversy about whether estrogen should be recommended in women in the first decade after the menopause; hopefully new research will provide guidance. In men, testosterone replacement therapy is also an effective treatment.
Estrogen replacement remains a good treatment for prevention of osteoporosis but, at this time, is not recommended unless there are other indications for its use as well. There is uncertainty and controversy about whether estrogen should be recommended in women in the first decade after the menopause; hopefully new research will provide guidance. In men, testosterone replacement therapy is also an effective treatment.


==References==
==References==

Revision as of 18:55, 22 July 2012

Osteoporosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteoporosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Life Style Modification
Pharmacotherapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteoporosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteoporosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteoporosis secondary prevention

CDC on Osteoporosis secondary prevention

Osteoporosis secondary prevention in the news

Blogs on Osteoporosis secondary prevention

Directions to Hospitals Treating Osteoporosis

Risk calculators and risk factors for Osteoporosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Raviteja Guddeti, M.B.B.S.[3]

Overview

Secondary prevention

Medication

Just as for treatment, bisphosphonate[1] can be used in cases of very high risk. Other medicines prescribed for prevention of osteoporosis include raloxifene (Evista), a selective estrogen receptor modulator (SERM).

Estrogen replacement remains a good treatment for prevention of osteoporosis but, at this time, is not recommended unless there are other indications for its use as well. There is uncertainty and controversy about whether estrogen should be recommended in women in the first decade after the menopause; hopefully new research will provide guidance. In men, testosterone replacement therapy is also an effective treatment.

References

  1. Zhang J, Wang R, Zhao YL; et al. (2012). "Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis". Asian Pac J Trop Med. 5 (9): 743–8. doi:10.1016/S1995-7645(12)60118-7. PMID 22805729. Unknown parameter |month= ignored (help)



Template:WikiDoc Sources